Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rsol-DSR Capsule
- Development stage
- Unknown
- Lead developer
- Solvix Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rsol-DSR Capsule is a combination pharmaceutical drug used to treat symptoms of acid reflux, stomach ulcers, peptic ulcer disease, Zollinger-Ellison syndrome, gastroesophageal reflux disease (GERD), duodenal ulcers, gastric ulcers, and Crohn's disease-associated ulcers. It contains two active ingredients: Rabeprazole, a proton pump inhibitor that reduces stomach acid production by blocking the H+/K+ ATPase enzyme, and Domperidone, a dopamine D2 receptor antagonist that increases the motility of the upper gastrointestinal tract and blocks the chemoreceptor trigger zone (CTZ) to prevent vomiting. The drug is manufactured by Solvix Pharma.
- Brand names
- Rsol-DSR Capsule
02
Targets
DRD2 (Dopamine D2 Receptor)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on Rsol-DSR Capsule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rsol-DSR Capsule.